Exelixis Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EXELIXIS, and what generic alternatives to EXELIXIS drugs are available?
EXELIXIS has two approved drugs.
There are eleven US patents protecting EXELIXIS drugs.
There are two hundred and seven patent family members on EXELIXIS drugs in thirty-two countries and nineteen supplementary protection certificates in sixteen countries.
Summary for Exelixis
| International Patents: | 207 |
| US Patents: | 11 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Exelixis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-002 | Nov 29, 2012 | RX | Yes | Yes | 9,717,720 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 11,091,439 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | 10,039,757 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 10,039,757 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Exelixis Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2387563 | ⤷ Try a Trial |
| Mexico | 2013009116 | ⤷ Try a Trial |
| Taiwan | 201735925 | ⤷ Try a Trial |
| Japan | 2011042686 | ⤷ Try a Trial |
| European Patent Office | 2392565 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Exelixis Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2213661 | 122014000091 | Germany | ⤷ Try a Trial | PRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321 |
| 2213661 | 583 | Finland | ⤷ Try a Trial | |
| 2213661 | 14C0067 | France | ⤷ Try a Trial | PRODUCT NAME: CABOZANTINIB ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE COUVERTE PAR LE BREVET DE BASE,INCLUANT SES SELS PHARMACEUTIQUEMENT EQUIVALENTS.; REGISTRATION NO/DATE: EU/1/13/890 20140326 |
| 2213661 | C20140029 00117 | Estonia | ⤷ Try a Trial | PRODUCT NAME: KABOSANTINIIB;REG NO/DATE: K(2014)2043 (LOPLIK) 26.03.2014 |
| 2213661 | C02213661/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66471 15.12.2017 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
